On Friday, Shares of InterXion Holding NV (NYSE:INXN), added 0.94% and closed at $37.42 in the last trading session. The last trading range of the stock ranges between $36.93 and $37.51. The company’s Market capitalization is $2.64 Billion with the total Outstanding Shares of 70.16 Billion. During the 52-week trading session the minimum price at which share price traded, registered at $26.75 and reached to max level of $38.72. Interxion Holding N.V. (INXN), a leading European provider of cloud-and carrier-neutral colocation data centre services, will release its third quarter 2016 results on Wednesday, 2 November 2016, and will host a conference call at 8:30 a.m. ET (12:30 p.m. GMT, 1:30 p.m. CET) to discuss the results.
To take part on this call, U.S. callers may dial toll free 1-866-966-9439; callers outside the U.S. may dial direct +44 (0) 1452 555 566. The conference ID for this call is INXN.
Shares of Threshold Pharmaceuticals, Inc. (NASDAQ:THLD), subtract -3.07% and closed at $0.550 in the last trading session. The last trading range of the stock ranges between $0.52 and $0.58. The company’s Market capitalization is $38.13 Billion with the total Outstanding Shares of 71.51Billion. During the 52-week trading session the minimum price at which share price traded, registered at $0.21 and reached to max level of $4.44. Threshold Pharmaceuticals, Inc. (THLD), a clinical-stage biopharmaceutical company specializing in the development of novel pharmaceutical products and technologies for the treatment of cancer, recently declared interim data from its two Phase 2 proof-of-concept clinical trials of tarloxotinib and outlined its plans to focus company resources on the more clinically-advanced evofosfamide program in addition to an earlier-stage anticancer candidate, TH-3424.
“While the response observed in our squamous cell carcinoma of the skin study with tarloxotinib was encouraging, the overall results from the two studies didn’t meet the activity thresholds required to move forward the molecule forward despite the promising results seen in preclinical translational studies,” said Barry Selick, Ph.D., Chief Executive Officer of Threshold. “As a result, we are making no further investment in this program. Instead, we plan to build on the efforts of our collaborator, Dr. Michael Curran of The University of Texas MD Anderson Cancer Center, to demonstrate the potential therapeutic value of adding evofosfamide to immune checkpoint inhibition, to continue to pursue negotiations with Japanese regulatory authorities regarding potential registration pathways for evofosfamide, and to advance TH-3424 through IND-enabling toxicology studies with the aim of reaching the clinic in 2017. We plan to provide additional operational guidance in the fourth quarter of 2016.”